Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 12c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
March 4, 2021 7:30 AM ESTInitiated Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients
On Track to Initiate Two Additional Clinical Trials Across Hematology Franchise in 2H 2021
On Track to Report Additional Dose-Escalation Data for SY-5609 in Select Solid Tumors in Q3 2021, with Expansion Phase of Trial Expected to Begin in 2H 2021
Well-funded with Cash Runway into 2023, Through Multiple Potential Value Drivers
Management to Host Conference Call at 8:30 a.m. ET Today
CAMBRIDGE,... More
